Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DAPA-LVH - Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes?

X
Trial Profile

DAPA-LVH - Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes?

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dapagliflozin (Primary)
  • Indications Left ventricular hypertrophy; Type 2 diabetes mellitus
  • Focus Proof of concept; Therapeutic Use
  • Acronyms DAPA-LVH
  • Most Recent Events

    • 01 Sep 2020 Results of a substudy assessing whether Dapagliflozin treatment improves Left Ventricular myocardial longitudinal function and Left Ventricular diastolic function in patients with T2DM and LVH, presented at the ESC Congress 2020 Annual Congress of the European Society of Cardiology
    • 24 Jun 2020 Results published in the European Heart Journal
    • 18 Nov 2019 Primary endpoint (Change in left ventricular (LV) Mass by Cardiac MRI at 52 weeks) has been met.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top